IL17A and sweet syndrome: Novelapproaches to treatment have also been reported such as immunoglobulin and Anakinra(IL-1 receptor antagonist) in refractory cases.5, , , -9 Efficacy of these treatmentstrategies and the variability in their mechanism of action, and advances in ourunderstanding of neutrophilic dermatoses’ pathophysiology, especially TNF-α, IL-1β,and IL-17, indicates that both innate and adaptive immune systems play a pivotalrole in pathogenesis of Sweet’s syndrome.